{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:23:33Z","timestamp":1790015013800,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["T32HD104576"],"award-info":[{"award-number":["T32HD104576"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD096435"],"award-info":[{"award-number":["R01HD096435"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD102949"],"award-info":[{"award-number":["R01HD102949"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40262-024-01418-8","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T14:13:19Z","timestamp":1726755199000},"page":"1435-1448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-4121","authenticated-orcid":false,"given":"Eleni","family":"Karatza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2110-3370","authenticated-orcid":false,"given":"Jaydeep","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-7408","authenticated-orcid":false,"given":"Patricia D.","family":"Maglalang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1653","authenticated-orcid":false,"given":"Andrea","family":"Edginton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-5686","authenticated-orcid":false,"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"10","key":"1418_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","volume":"17","author":"M Romoli","year":"2019","unstructured":"Romoli M, Mazzocchetti P, D\u2019Alonzo R, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926\u201346.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"1418_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1753-2000-2-24","volume":"2","author":"JM Zito","year":"2008","unstructured":"Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health. 2008;2(1):24.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"11","key":"1418_CR3","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1080\/03639045.2017.1342654","volume":"43","author":"R Savla","year":"2017","unstructured":"Savla R, Browne J, Plassat V, Wasan KM, Wasan EK. Review and analysis of FDA approved drugs using lipid-based formulations. Drug Dev Ind Pharm. 2017;43(11):1743\u201358.","journal-title":"Drug Dev Ind Pharm"},{"key":"1418_CR4","unstructured":"Depacon (valproate sodium) for intravenous injection Package Insert. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020593s026lbl.pdf. Accessed 10 Feb 2024."},{"issue":"3","key":"1418_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eplepsyres.2006.11.005","volume":"73","author":"S Dutta","year":"2007","unstructured":"Dutta S, Reed RC. Distinct absorption characteristics of oral formulations of valproic acid\/divalproex available in the United States. Epilepsy Res. 2007;73(3):275\u201383.","journal-title":"Epilepsy Res"},{"issue":"4","key":"1418_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2710.2007.00831.x","volume":"32","author":"S Dutta","year":"2007","unstructured":"Dutta S, Faught E, Limdi NA. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy. J Clin Pharm Ther. 2007;32(4):365\u201371.","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"1418_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE commission on therapeutic strategies. Epilepsia. 2008;49(7):1239\u201376.","journal-title":"Epilepsia"},{"key":"1418_CR8","unstructured":"Rahman M, Awosika AO, Nguyen H. Valproic acid. [Updated 2024 Mar 19]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559112\/.  Accessed 24 June 2024."},{"issue":"3","key":"1418_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.mjt.0000155113.89092.58","volume":"13","author":"D Panomvana Na Ayudhya","year":"2006","unstructured":"Panomvana Na Ayudhya D, Suwanmanee J, Visudtibhan A. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Am J Ther. 2006;13(3):211\u20137.","journal-title":"Am J Ther"},{"issue":"Pt 1","key":"1418_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/0004563215593561","volume":"53","author":"G Weaving","year":"2016","unstructured":"Weaving G, Batstone GF, Jones RG. Age and sex variation in serum albumin concentration: an observational study. Ann Clin Biochem. 2016;53(Pt 1):106\u201311.","journal-title":"Ann Clin Biochem"},{"key":"1418_CR11","doi-asserted-by":"publisher","unstructured":"Mclntyre N, Rosalki S. Tests of the functions of the liver. In: Williams DL, Marks V, editors. Scientific foundations of biochemistry in clinical practice, 2nd ed. 1994. p. 383\u201398.https:\/\/doi.org\/10.1016\/B978-0-7506-0167-2.50027-3","DOI":"10.1016\/B978-0-7506-0167-2.50027-3"},{"key":"1418_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ejps.2017.10.009","volume":"111","author":"TM Conner","year":"2018","unstructured":"Conner TM, Nikolian VC, Georgoff PE, et al. Physiologically based pharmacokinetic modeling of disposition and drug\u2013drug interactions for valproic acid and divalproex. Eur J Pharm Sci. 2018;111:465\u201381.","journal-title":"Eur J Pharm Sci"},{"key":"1418_CR13","unstructured":"Depakene (valproic acid) Package insert. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/018081s071,018082s054lbl.pdf. Accessed 10 Feb 2024."},{"issue":"3","key":"1418_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/FTD.0000000000000405","volume":"39","author":"E Wallenburg","year":"2017","unstructured":"Wallenburg E, Klok B, de Jong K, et al. Monitoring protein-unbound valproic acid serum concentrations in clinical practice. Ther Drug Monit. 2017;39(3):269\u201372.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"1418_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/jcph.2071","volume":"62","author":"PM Burkat","year":"2022","unstructured":"Burkat PM. Physiologically based pharmacokinetic and pharmacodynamic modeling of diazepam: unbound interstitial brain concentrations correspond to clinical end points. J Clin Pharmacol. 2022;62(10):1297\u2013309.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1418_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005280","volume":"13","author":"C Thiel","year":"2017","unstructured":"Thiel C, Cordes H, Fabbri L, et al. A comparative analysis of drug-induced hepatotoxicity in clinically relevant situations. PLoS Comput Biol. 2017;13(2): e1005280.","journal-title":"PLoS Comput Biol"},{"key":"1418_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejps.2014.06.023","volume":"63","author":"K Ogungbenro","year":"2014","unstructured":"Ogungbenro K, Aarons L, CRESim & Epi-CRESim Project Groups. A physiologically based pharmacokinetic model for valproic acid in adults and children. Eur J Pharm Sci. 2014;63:45\u201352.","journal-title":"Eur J Pharm Sci."},{"issue":"6","key":"1418_CR18","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases [published correction appears in J Pharm Sci. 2007 Nov;96(11):3151-2]. J Pharm Sci. 2005;94(6):1259\u201376.","journal-title":"J Pharm Sci."},{"issue":"2","key":"1418_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1208\/s12248-013-9451-0","volume":"15","author":"AR Maharaj","year":"2013","unstructured":"Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15(2):455\u201364.","journal-title":"AAPS J"},{"issue":"2","key":"1418_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00007691-198903000-00002","volume":"11","author":"RG Dickinson","year":"1989","unstructured":"Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit. 1989;11(2):127\u201333.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1418_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/clpt.1990.144","volume":"48","author":"RH Levy","year":"1990","unstructured":"Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther. 1990;48(3):225\u201335.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1418_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","volume":"23","author":"Y Ghodke-Puranik","year":"2013","unstructured":"Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4):236\u201341.","journal-title":"Pharmacogenet Genomics"},{"key":"1418_CR23","unstructured":"Open Systems Pharmacology Suite Manual Version 7.0 Publication. Open Systems Pharmacology Suite Community License. 2017."},{"key":"1418_CR24","doi-asserted-by":"crossref","unstructured":"Parkinson H, Sarkans U, Kolesnikov N, et al. ArrayExpress update\u2014an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res. 2011;39(Database issue):D1002\u2013D1004.","DOI":"10.1093\/nar\/gkq1040"},{"issue":"10","key":"1418_CR25","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s11095-005-6650-0","volume":"22","author":"DE Mager","year":"2005","unstructured":"Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589\u201396.","journal-title":"Pharm Res"},{"issue":"7","key":"1418_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1211\/jpp.62.07.0004","volume":"62","author":"VK Llewelyn","year":"2010","unstructured":"Llewelyn VK, Mangan MF, Glass BD. Stability of sodium valproate tablets repackaged into dose administration aids. J Pharm Pharmacol. 2010;62(7):838\u201343.","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"1418_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jsps.2016.04.006","volume":"24","author":"S Yang","year":"2016","unstructured":"Yang S, Wang X, Jia J, Li P. Release property study on the novel divalproex sodium enteric-coated capsules. Saudi Pharm J. 2016;24(3):245\u20139.","journal-title":"Saudi Pharm J"},{"key":"1418_CR28","first-page":"21","volume":"1","author":"J Akhtar","year":"2011","unstructured":"Akhtar J, Rana P, Jhanwar B. Formulation and evaluation of divalproex sodium enteric coated tablets. J Sci. 2011;1:21.","journal-title":"J Sci"},{"key":"1418_CR29","unstructured":"Qiu Y, Bollinger JD, et al, inventors; Abbott Laboratories, assignee. Controlled release formulation of divalproex sodium. US 6,720,004 B2. April 13, 2004."},{"issue":"11\u2013107","key":"1418_CR30","first-page":"S65","volume":"42","author":"W Denney","year":"2015","unstructured":"Denney W, Duvvuri S, Buckeridge C. Simple, automatic noncompartmental analysis: the PKNCA R package. J Pharmacokinet Pharmacodyn. 2015;42(11\u2013107):S65.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"1418_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/archpedi.161.11.1048","volume":"161","author":"IN Horowitz","year":"2007","unstructured":"Horowitz IN, Tai K. Hypoalbuminemia in critically ill children. Arch Pediatr Adolesc Med. 2007;161(11):1048\u201352.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"1418_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2710.1993.tb00612.x","volume":"18","author":"MJ G\u00f3mez Bellver","year":"1993","unstructured":"G\u00f3mez Bellver MJ, Garc\u00eda S\u00e1nchez MJ, Alonso Gonz\u00e1lez AC, Santos Buelga D, Dom\u00ednguez-Gil A. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharm Ther. 1993;18(3):191\u20137.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1418_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40262-018-0681-2","volume":"58","author":"J Bad\u00e9e","year":"2019","unstructured":"Bad\u00e9e J, Fowler S, de Wildt SN, Collier AC, Schmidt S, Parrott N. The ontogeny of UDP-glucuronosyltransferase enzymes, recommendations for future profiling studies and application through physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2019;58(2):189\u2013211.","journal-title":"Clin Pharmacokinet"},{"key":"1418_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/B978-0-12-802949-7.00008-0","volume-title":"Drug metabolism in diseases","author":"EHJ Krekels","year":"2017","unstructured":"Krekels EHJ, Rower JE, Constance JE, Knibbe CAJ, Sherwin CMT. Hepatic drug metabolism in pediatric patients. In: Drug metabolism in diseases. Amsterdam: Elsevier Inc.; 2017. p. 181\u2013206."},{"issue":"5","key":"1418_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10545-010-9104-8","volume":"33","author":"RJ Wanders","year":"2010","unstructured":"Wanders RJ, Ruiter JP, Ijlst L, Waterham HR, Houten SM. The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results. J Inherit Metab Dis. 2010;33(5):479\u201394.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"1418_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/pr.2015.237","volume":"79","author":"PK Sethi","year":"2016","unstructured":"Sethi PK, White CA, Cummings BS, Hines RN, Muralidhara S, Bruckner JV. Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin. Pediatr Res. 2016;79(3):409\u201315.","journal-title":"Pediatr Res"},{"key":"1418_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0378-5173(85)90219-4","volume":"23","author":"M Bialer","year":"1985","unstructured":"Bialer M, Rubinstein A, Dubrovsky J, Raz I, Abramsky O. A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. Int J Pharm. 1985;23:25\u201333.","journal-title":"Int J Pharm"},{"issue":"7","key":"1418_CR38","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/0091270004266782","volume":"44","author":"S Dutta","year":"2004","unstructured":"Dutta S, Reed RC, Cavanaugh JH. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol. 2004;44(7):737\u201342.","journal-title":"J Clin Pharmacol"},{"key":"1418_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1365-2125.1978.tb01713.x","volume":"5","author":"E Perucca","year":"1978","unstructured":"Perucca E, Gatti G, Frigo GM, Crema A. Pharmacokinetics of valproic acid after oral and intravenous administration. Br J Clin Pharmacol. 1978;5:313\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1418_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1528-1157.1982.tb05063.x","volume":"23","author":"V Nitsche","year":"1982","unstructured":"Nitsche V, Mascher H. The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. Epilepsia. 1982;23(2):153\u201362.","journal-title":"Epilepsia"},{"issue":"2","key":"1418_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-017-0553-1","volume":"57","author":"PE Georgoff","year":"2018","unstructured":"Georgoff PE, Nikolian VC, Bonham T, et al. Safety and tolerability of intravenous valproic acid in healthy subjects: a phase I dose-escalation trial. Clin Pharmacokinet. 2018;57(2):209\u201319.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1418_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/j.1552-4604.1980.tb01663.x","volume":"20","author":"AH Chun","year":"1980","unstructured":"Chun AH, Hoffman DJ, Friedmann N, Carrigan PJ. Bioavailability of valproic acid under fasting\/nonfasting regimens. J Clin Pharmacol. 1980;20(1):30\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1418_CR43","first-page":"629","volume":"38","author":"G Bano","year":"1990","unstructured":"Bano G, Gupta S, Gupta KL, Raina RK. Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults. J Assoc Physicians India. 1990;38(9):629\u201330.","journal-title":"J Assoc Physicians India"},{"issue":"3","key":"1418_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2125.1989.tb05372.x","volume":"27","author":"SK Panesar","year":"1989","unstructured":"Panesar SK, Orr JM, Farrell K, Burton RW, Kassahun K, Abbott FS. The effect of carbamazepine on valproic acid disposition in adult volunteers. Br J Clin Pharmacol. 1989;27(3):323\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1418_CR45","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/j.1552-4604.1990.tb03637.x","volume":"30","author":"PJ Carrigan","year":"1990","unstructured":"Carrigan PJ, Brinker DR, Cavanaugh JH, Lamm JE, Cloyd JC. Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). J Clin Pharmacol. 1990;30(8):743\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1418_CR46","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.2147\/DDDT.S89464","volume":"9","author":"SY Lee","year":"2015","unstructured":"Lee SY, Huh W, Jung JA, Yoo HM, Ko JW, Kim JR. Effects of amoxicillin\/clavulanic acid on the pharmacokinetics of valproic acid. Drug Des Devel Ther. 2015;9:4559\u201363.","journal-title":"Drug Des Devel Ther."},{"issue":"4","key":"1418_CR47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1345\/aph.1G617","volume":"40","author":"S Dutta","year":"2006","unstructured":"Dutta S, Reed RC, O\u2019Dea RF. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets\u2014clinical implications. Ann Pharmacother. 2006;40(4):619\u201325.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1418_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/bdd.2510060105","volume":"6","author":"M Bialer","year":"1985","unstructured":"Bialer M, Hussein Z, Raz I, Abramsky O, Herishanu Y, Pachys F. Pharmacokinetics of valproic acid in volunteers after a single dose study. Biopharm Drug Dispos. 1985;6(1):33\u201342.","journal-title":"Biopharm Drug Dispos"},{"issue":"11","key":"1418_CR49","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1177\/0091270011428138","volume":"52","author":"JH Williams","year":"2012","unstructured":"Williams JH, Jayaraman B, Swoboda KJ, Barrett JS. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. J Clin Pharmacol. 2012;52(11):1676\u201388.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1418_CR50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.braindev.2010.04.003","volume":"33","author":"A Visudtibhan","year":"2011","unstructured":"Visudtibhan A, Bhudhisawadi K, Vaewpanich J, Chulavatnatol S, Kaojareon S. Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. Brain Dev. 2011;33(3):189\u201394.","journal-title":"Brain Dev"},{"issue":"1\u20132","key":"1418_CR51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0920-1211(02)00251-6","volume":"53","author":"JC Cloyd","year":"2003","unstructured":"Cloyd JC, Dutta S, Cao G, et al. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 2003;53(1\u20132):19\u201327.","journal-title":"Epilepsy Res"},{"issue":"5","key":"1418_CR52","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pediatrneurol.2003.12.006","volume":"30","author":"S Dutta","year":"2004","unstructured":"Dutta S, Zhang Y, Conway JM, et al. Divalproex-ER pharmacokinetics in older children and adolescents. Pediatr Neurol. 2004;30(5):330\u20137.","journal-title":"Pediatr Neurol"},{"key":"1418_CR53","doi-asserted-by":"crossref","unstructured":"Wishart D, Knox C, Guo A, Shrivastava S, Hassanali M, Stothard P, et al. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Valproic acid. Nucleic Acids Res. 2006;1:(Database issue):D668\u201372.","DOI":"10.1093\/nar\/gkj067"},{"key":"1418_CR54","unstructured":"Depakene (valproic acid) capsules and oral solution package insert. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018081s056lbl.pdf. Accessed 22 June 2022."},{"key":"1418_CR55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000268055","volume":"36","author":"JD Hoppe","year":"2009","unstructured":"Hoppe JD, Scriba PC, Kl\u00fcter H. Transfusion medicine and hemotherapy: preface. Transfusion Med Hemother. 2009;36:353\u20134.","journal-title":"Transfusion Med Hemother"},{"issue":"9","key":"1418_CR56","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1124\/dmd.121.000474","volume":"49","author":"RH Takahashi","year":"2021","unstructured":"Takahashi RH, Forrest WF, Smith AD, et al. Characterization of hepatic UDP-glucuronosyltransferase enzyme abundance-activity correlations and population variability using a proteomics approach and comparison with cytochrome P450 enzymes. Drug Metab Dispos. 2021;49(9):760\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1418_CR57","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1124\/dmd.113.055632","volume":"42","author":"B Achour","year":"2014","unstructured":"Achour B, Russell MR, Barber J, Rostami-Hodjegan A. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5\u2019-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos. 2014;42(4):500\u201310.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1418_CR58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","volume":"3","author":"PC Ho","year":"2003","unstructured":"Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 2003;3(6):335\u201342.","journal-title":"Pharmacogenomics J"},{"issue":"9","key":"1418_CR59","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1124\/dmd.115.065391","volume":"43","author":"G Margaillan","year":"2015","unstructured":"Margaillan G, Rouleau M, Klein K, et al. Multiplexed targeted quantitative proteomics predicts hepatic glucuronidation potential. Drug Metab Dispos. 2015;43(9):1331\u20135.","journal-title":"Drug Metab Dispos"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01418-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:18:05Z","timestamp":1730297885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01418-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01418-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"13 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded under the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under award numbers R01HD096435 and R01HD102949. P.D.M. receives support from the Eunice Kennedy Shriver NICHD of the NIH under Award Number T32HD104576. The content is solely the authors\u2019 responsibility and does not necessarily represent the official views of the National Institutes of Health. E.K. was funded through a UNC\/GlaxoSmithKline pharmacokinetics\/pharmacodynamics postdoctoral fellowship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"E.K. is currently an employee at J&J Innovative Medicines and holds stocks of J&J; her current affiliation has no scientific or financial bearing on this work nor the content of this manuscript. Andrea Edginton is an Editorial Board member of Clinical Pharmacokinetics. Andrea Edginton was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The rest of the authors have no relevant conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The PK-Sim<sup>\u00ae<\/sup> model file will be provided upon reasonable request by contacting the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The PBPK analyses described in this publication were approved by the University of North Carolina at Chapel Hill Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All data included in this publication were obtained from the literature.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"E.K., J.S., P.D.M., A.E., and D.G. designed and performed the research; E.K., J.S., and P.D.M. analyzed the data; E.K., J.S., P.D.M., A.E., M.S., A.H., and D.G. wrote or contributed to the writing of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}